IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 46.540
AS - Asia 8.317
EU - Europa 5.973
Continente sconosciuto - Info sul continente non disponibili 1.096
SA - Sud America 1.077
AF - Africa 182
OC - Oceania 98
Totale 63.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 45.892
SG - Singapore 3.621
CN - Cina 1.710
IT - Italia 1.341
RU - Federazione Russa 977
HK - Hong Kong 911
BR - Brasile 866
DE - Germania 604
VN - Vietnam 570
FR - Francia 569
IE - Irlanda 503
BD - Bangladesh 453
UA - Ucraina 420
GB - Regno Unito 386
FI - Finlandia 337
CA - Canada 308
JP - Giappone 255
SE - Svezia 220
PL - Polonia 160
IN - India 128
KR - Corea 126
NL - Olanda 120
ID - Indonesia 78
AR - Argentina 71
MX - Messico 64
ES - Italia 60
TR - Turchia 56
TW - Taiwan 56
AU - Australia 55
ZA - Sudafrica 52
BE - Belgio 51
AT - Austria 50
NZ - Nuova Zelanda 43
DK - Danimarca 42
IL - Israele 39
CR - Costa Rica 38
EC - Ecuador 37
UZ - Uzbekistan 37
CO - Colombia 36
IQ - Iraq 36
JM - Giamaica 35
TT - Trinidad e Tobago 34
EG - Egitto 32
PK - Pakistan 30
IR - Iran 29
SA - Arabia Saudita 26
GT - Guatemala 25
NI - Nicaragua 25
PR - Porto Rico 25
MY - Malesia 24
PH - Filippine 24
SV - El Salvador 24
AE - Emirati Arabi Uniti 23
HN - Honduras 23
SC - Seychelles 19
VE - Venezuela 19
CH - Svizzera 18
GP - Guadalupe 15
TH - Thailandia 15
CL - Cile 14
LT - Lituania 14
MA - Marocco 14
RO - Romania 14
GR - Grecia 13
NP - Nepal 13
CW - ???statistics.table.value.countryCode.CW??? 12
NG - Nigeria 12
KE - Kenya 11
LV - Lettonia 11
PE - Perù 10
HU - Ungheria 9
PY - Paraguay 9
TN - Tunisia 9
AZ - Azerbaigian 8
BG - Bulgaria 8
ET - Etiopia 8
KG - Kirghizistan 8
HR - Croazia 7
UY - Uruguay 7
DO - Repubblica Dominicana 6
SI - Slovenia 6
BB - Barbados 5
BO - Bolivia 5
DZ - Algeria 5
KH - Cambogia 5
LB - Libano 5
OM - Oman 5
AL - Albania 4
CZ - Repubblica Ceca 4
JO - Giordania 4
KW - Kuwait 4
KZ - Kazakistan 4
PA - Panama 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BS - Bahamas 3
CI - Costa d'Avorio 3
EE - Estonia 3
EU - Europa 3
LC - Santa Lucia 3
Totale 62.141
Salva come PNG Salva come JPEG
Città #
Wilmington 10.073
Woodbridge 9.296
Houston 9.147
Ashburn 1.953
Singapore 1.908
Fairfield 1.283
San Jose 1.137
Ann Arbor 982
Hong Kong 896
Chandler 800
Seattle 532
Dallas 489
Council Bluffs 487
Beijing 467
New York 464
Cambridge 441
Dublin 425
Santa Clara 380
Los Angeles 360
Jacksonville 342
Medford 329
Columbus 303
The Dalles 294
Rome 257
Helsinki 216
Ho Chi Minh City 206
Tokyo 200
Zhengzhou 159
Moscow 155
Lawrence 153
Lauterbourg 138
Dearborn 132
Denver 132
Milan 131
Buffalo 128
São Paulo 116
Hanoi 114
North Bergen 114
Chicago 108
Elk Grove Village 108
Kraków 94
San Diego 79
Toronto 75
Munich 73
London 68
Atlanta 63
Redwood City 63
Brooklyn 62
Montreal 61
Phoenix 60
Menlo Park 59
Redondo Beach 56
Nuremberg 55
Orem 55
Nanjing 53
Warsaw 53
Naples 52
Shanghai 52
Boardman 51
Seoul 51
Brussels 45
Amsterdam 44
Guangzhou 44
Philadelphia 44
Tauranga 42
Frankfurt am Main 41
Stockholm 41
Jakarta 39
San Francisco 38
Chaozhou 37
Norwalk 37
Copenhagen 36
Shenzhen 36
Chengdu 35
Florence 35
Johannesburg 34
Chennai 30
Boston 28
Palo Alto 28
San José 28
Las Vegas 27
Hefei 26
Lappeenranta 26
Suzhou 26
Managua 25
Mülheim 25
Taipei 25
Belo Horizonte 24
Bologna 24
Melbourne 24
Rio de Janeiro 24
Da Nang 23
Washington 23
Brasília 22
Falls Church 22
Haiphong 22
Manchester 21
Memphis 20
Mountain View 20
San Salvador 20
Totale 47.801
Salva come PNG Salva come JPEG
Nome #
Challenges in the treatment of Rheumatoid Arthritis 913
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 678
Complement, infection, and autoimmunity 626
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 607
Efficacy and safety of infliximab in psoriatic patients over the age of 65 568
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 560
Complement and autoimmunity 552
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 545
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 537
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 536
Autoantibodies in inflammatory arthritis 529
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 522
Vasculitides and the Complement System: a Comprehensive Review 516
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 511
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 504
Apremilast for the treatment of psoriasis. 500
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 499
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 486
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 485
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 485
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 482
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 482
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 482
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 481
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 480
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 480
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 475
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 473
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 473
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 473
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 468
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 468
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 468
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 467
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 463
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 463
IL-21 in the pathogenesis and treatment of skin diseases 461
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 458
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 456
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 455
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 454
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 453
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 450
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 449
Auto-reactions, autoimmunity and psoriatic arthritis 449
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 448
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 448
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 447
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 446
The significance of the development of antinuclear antibodies during infliximab treatment 444
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 443
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 442
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 438
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 437
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 431
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 431
Nintedanib in Rheumatoid Arthritis–Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation 429
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 429
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 427
The interplay between inflammation and metabolism in rheumatoid arthritis 427
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 425
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 423
Insights on the role of physical activity in patients with rheumatoid arthritis 423
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 422
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 422
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 414
Skin reaction associated with chrysotherapy: an unusual case 413
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 408
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 401
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 399
Small molecule therapy for managing moderate to severe psoriatic arthritis 399
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 395
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 394
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 393
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 393
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 392
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 390
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 387
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 383
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 380
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 379
Histopathology of the skin in rheumatic diseases 376
Tofacitinib for the treatment of moderate-to-severe psoriasis 372
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 367
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 367
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 364
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 359
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 358
Hereditary angioedema and autoimmunity 357
Treatment of Hailey-Hailey disease with topical calcitriol 356
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 352
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 350
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 347
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 331
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases 328
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 328
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 325
Interaction between microbiome and host genetics in psoriatic arthritis 319
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 297
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 287
Totale 44.364
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.161 0 0 0 0 50 86 86 87 93 122 173 464
2022/20232.026 207 176 88 255 188 450 163 135 182 41 103 38
2023/20241.061 95 30 36 28 131 266 43 137 58 19 53 165
2024/20255.419 182 1.196 625 307 71 404 281 214 405 449 698 587
2025/202611.857 690 1.096 1.264 1.187 1.075 415 1.275 1.269 1.134 1.027 834 591
2026/20275.873 744 864 2.073 1.881 311 0 0 0 0 0 0 0
Totale 63.283